US EditionAssembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights - Assembly Biosciences (NASDAQ:ASMB)
Summary by Benzinga
2 Articles
2 Articles
All
Left
Center
2
Right
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights - Assembly Biosciences (NASDAQ:ASMB)
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB)…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
